| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Fmoc-Asp(ODmab)-OH has no biological target; it is a chemical intermediate. The Fmoc group enables SPPS, and the side-chain protection allows selective deprotection. The ODmab group provides quasi-orthogonal protection that is cleavable under mild hydrazine conditions, which is a significant advantage over other protecting group strategies. The compound's "target" is the peptide bond formation process in solid-phase peptide synthesis, where it acts as a protected aspartic acid donor. The Dmab group represents an unhindered p-substituted Z-derivative, but Asp(Dmab)-containing peptides are prone to base-catalyzed aspartimide formation, which must be considered during synthesis design. The compound's utility lies entirely in the chemical synthesis domain.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of Fmoc-Asp(ODmab)-OH is evaluated by coupling efficiency in SPPS. Typically, it is coupled to resin-bound amine using HATU/DIEA in DMF for 1-2 hours. Cleavage and deprotection yield the desired peptide. HPLC purity typically >95%. The compound demonstrates high coupling efficiency and selective deprotection capabilities. The compound's reactivity is characterized by the successful formation of peptide bonds under standard Fmoc SPPS conditions. The compound has been used by Conroy et al. for the solid-phase synthesis of N-linked glycopeptides. Quality control includes assay ≥96.0% (HPLC) and ≥98% (TLC). The compound is available in powder form with a quality level of 200. |
| ln Vivo |
In vivo activity is not applicable for Fmoc-Asp(ODmab)-OH. The compound is not used in animals. It is a research chemical for laboratory synthesis only.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow for Fmoc-Asp(ODmab)-OH involves standard Fmoc SPPS procedures. Standard SPPS cycle: deprotect Fmoc with 20% piperidine in DMF, couple Fmoc-Asp(ODmab)-OH (3 equiv.) with HATU (2.9 equiv.) and DIEA (6 equiv.) for 2 hours, wash, repeat. After synthesis, cleave with TFA/TIS/H₂O. Analyze by HPLC-MS. The ODmab group can be cleaved selectively in the presence of tBu-based protected groups by treatment with 2% hydrazine in DMF. The compound serves as a key building block in the synthesis of peptides, facilitating the incorporation of aspartic acid into peptide chains, which is crucial for developing various therapeutic proteins. The compound is a quasi-orthogonally protected Asp derivative. For application information, refer to entry for 852079.
|
| Cell Assay |
In vitro cell-based experimental workflows are not performed on this intermediate. The final deprotected peptides may be tested in cell-based assays, but the protected compound itself is not used.
|
| Animal Protocol |
In vivo animal experiments are not applicable for Fmoc-Asp(ODmab)-OH. The compound is stored at -20°C.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Fmoc-Asp(ODmab)-OH have not been characterized. The compound is not a drug. No ADME data are available. The compound is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
The toxicological data for Fmoc-Asp(ODmab)-OH are not well-documented. Standard laboratory safety practices should be followed. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
Fmoc-Asp(ODmab)-OH is a quasi-orthogonally protected aspartic acid derivative used in Fmoc solid-phase peptide synthesis (SPPS). The compound incorporates the ODmab ester protecting group on the β-carboxy side chain. The Dmab group can be cleaved selectively in the presence of tBu-based protected groups by treatment with 2% hydrazine in DMF, making this derivative an extremely useful tool for the preparation of cyclic peptides by Fmoc SPPS. The compound has been used for the solid-phase synthesis of N-linked glycopeptides. As Dmab represents an unhindered p-substituted Z-derivative, Asp(Dmab)-containing peptides are prone to base-catalyzed aspartimide formation. The compound is available from multiple suppliers including Novabiochem®. It is not a drug and has no clinical trials or approvals. The compound is for research use only.
|
| Molecular Formula |
C39H42N2O8
|
|---|---|
| Molecular Weight |
666.76
|
| Exact Mass |
666.294
|
| CAS # |
269066-08-2
|
| PubChem CID |
135742652
|
| Appearance |
White to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
841.0±65.0 °C at 760 mmHg
|
| Flash Point |
462.4±34.3 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.608
|
| LogP |
7.04
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
49
|
| Complexity |
1260
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)CC(=NC1=CC=C(C=C1)COC(=O)C[C@@H](C(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24)C5=C(CC(CC5=O)(C)C)O
|
| InChi Key |
RZOFMGBIWZZRKU-YTTGMZPUSA-N
|
| InChi Code |
InChI=1S/C39H42N2O8/c1-23(2)17-31(36-33(42)19-39(3,4)20-34(36)43)40-25-15-13-24(14-16-25)21-48-35(44)18-32(37(45)46)41-38(47)49-22-30-28-11-7-5-9-26(28)27-10-6-8-12-29(27)30/h5-16,23,30,32,42H,17-22H2,1-4H3,(H,41,47)(H,45,46)/t32-/m0/s1
|
| Chemical Name |
(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[[4-[[1-(2-hydroxy-4,4-dimethyl-6-oxocyclohexen-1-yl)-3-methylbutylidene]amino]phenyl]methoxy]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4998 mL | 7.4990 mL | 14.9979 mL | |
| 5 mM | 0.3000 mL | 1.4998 mL | 2.9996 mL | |
| 10 mM | 0.1500 mL | 0.7499 mL | 1.4998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
